

Nephrectomy versus no nephrectomy for metastatic renal carcinoma

| | | |
|----------------------------------------|---------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| Submission date 28/02/2001 | Recruitment status No longer recruiting | <input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol |
| Registration date 28/02/2001 | Overall study status Completed | <input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results |
| Last Edited 26/02/2016 | Condition category Cancer | <input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year |

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Pat Cook

Contact details
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
RE03

Study information

Scientific Title

Nephrectomy versus no nephrectomy for metastatic renal carcinoma

Study objectives

To establish whether, in patients with metastatic renal carcinoma, nephrectomy has any advantage.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Renal Cancer

Interventions

1. One group receives a nephrectomy
2. The other receives no nephrectomy

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

1. Time to progression
2. Metastase rate
3. Quality of life
4. Survival time

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/1995

Completion date

01/12/1998

Eligibility

Key inclusion criteria

1. Patient should have locally operable disease and should be fit enough for nephrectomy
2. A renal tumour with clinical or radiological evidence of metastases
3. No previous malignancy (except non-melanotic skin cancer or in situ carcinoma of the cervix)
4. Written informed consent of the patient

Participant type(s)

Patient

Age group

Not Specified

Sex

Not Specified

Target number of participants

120

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/1995

Date of final enrolment

01/12/1998

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

MRC Clinical Trials Unit

London

United Kingdom

NW1 2DA

Sponsor information

Organisation

Medical Research Council (MRC) (UK)

Sponsor details

20 Park Crescent

London

United Kingdom

W1B 1AL

+44 (0)20 7636 5422

clinical.trial@headoffice.mrc.ac.uk

Sponsor type

Research council

Website

<http://www.mrc.ac.uk>

Funder(s)

Funder type

Research council

Funder Name

Medical Research Council (MRC) (UK)

Alternative Name(s)

Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration